High Antigenicity for T reg Cells Confers Resistance to PD ‐1 Blockade Therapy via High PD ‐1 Expression in T reg Cells
Cancer Science · 2025-05 · 116 (5) · 1214-1226
DOI: 10.1111/cas.70029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 27.02.2025. Verfasst von Hiroaki Matsuura und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tumor Microenvironment, Okayama University, Okayama, Japan. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Programmed Cell Death 1 Receptor, Drug Resistance, Neoplasm, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UBE Foundation, Japanese Respiratory Foundation, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Regulatory T (T reg ) cells have an immunosuppressive function, and programmed death‐1 (PD‐1)‐expressing T reg cells reportedly induce resistance to PD‐1 blockade therapies through their reactivation. However, the effects of antigenicity on PD‐1 expression in T reg cells and the resistance to PD‐1 blockade therapy remain unclear. Here, we show that T reg cells gain high PD‐1 expression through an antigen with high antigenicity. Additionally, tumors with high antigenicity for T reg cells were resistant to PD‐1 blockade in vivo due to PD‐1 + T reg ‐cell infiltration. Because such PD‐1 + T reg cells have high cytotoxic T lymphocyte antigen (CTLA)‐4 expression, resistance could be overcome by combination with an anti‐CTLA‐4 monoclonal antibody (mAb). Patients who responded to combination therapy with anti‐PD‐1 and anti‐CTLA‐4 mAbs sequentially after primary resistance to PD‐1 blockade monotherapy showed high T reg cell infiltration. We propose that the high antigenicity of T reg cells confers resistance to PD‐1 blockade therapy via high PD‐1 expression in T reg cells, which can be overcome by combination therapy with an anti‐CTLA‐4 mAb.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Tumor Microenvironment, Okayama University, Okayama, Japan.
- Department of Hematology, Oncology and Respiratory Medicine, Okayama University, Okayama, Japan.
- Department of Dermatology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
- Department of Dermatology, University of Yamanashi, Yamanashi, Japan.
- Department of Dermatology, Chiba University, Chiba, Japan.
- Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
ORCID-Profile: Hiroaki Matsuura, Kadoaki Ohashi, Yosuke Togashi
Förderung
- UBE Foundation
- Japanese Respiratory Foundation
- Japan Society for the Promotion of Science
- MSD Life Science Foundation, Public Interest Incorporated Foundation
- Japan Science and Technology Agency
- Daiichi Sankyo Foundation of Life Science
- Ryobi Teien Memory Foundation
- Japan Agency for Medical Research and Development
Zitieren
APA
Matsuura, H., Ishino, T., Ninomiya, T., Ninomiya, K., Tachibana, K., Honobe-Tabuchi, A., Muto, Y., Inozume, T., Ueda, Y., Ohashi, K., Maeda, Y., Nagasaki, J., & Togashi, Y. (2025). High Antigenicity for T reg Cells Confers Resistance to PD ‐1 Blockade Therapy via High PD ‐1 Expression in T reg Cells. Cancer Science, 116(5), 1214-1226. https://doi.org/10.1111/cas.70029
Vancouver
Matsuura H, Ishino T, Ninomiya T, Ninomiya K, Tachibana K, Honobe-Tabuchi A, et al. High Antigenicity for T reg Cells Confers Resistance to PD ‐1 Blockade Therapy via High PD ‐1 Expression in T reg Cells. Cancer Science. 2025;116(5):1214-1226. doi:10.1111/cas.70029
BibTeX
@article{Matsuura2025,
author = {Matsuura, Hiroaki and Ishino, Takamasa and Ninomiya, Toshifumi and Ninomiya, Kiichiro and Tachibana, Kota and Honobe-Tabuchi, Akiko and Muto, Yoshinori and Inozume, Takashi and Ueda, Youki and Ohashi, Kadoaki and Maeda, Yoshinobu and Nagasaki, Joji and Togashi, Yosuke},
title = {High Antigenicity for T reg Cells Confers Resistance to PD ‐1 Blockade Therapy via High PD ‐1 Expression in T reg Cells},
journal = {Cancer Science},
year = {2025},
volume = {116},
number = {5},
pages = {1214--1226},
doi = {10.1111/cas.70029}
}
EUVIMED